AVITA Medical Q2 2026 Earnings: Recovery Narrative Reaffirmed, Execution Remains Critical

What happened

AVITA Medical reported second-quarter 2026 results, with management highlighting gradual progress in reimbursement advocacy and a modest sequential improvement in procedure volumes after the demand softness seen in early 2025. The RECELL GO system added a small number of new accounts, though per-center utilization growth was tepid, constrained by training curves and lingering payer uncertainty. Early contributions from Cohealyx and PermeaDerm were noted but remained immaterial to overall revenue. Cash balances continued to decline, and interest payments further pressured liquidity, keeping the focus on the pace of the revenue ramp needed to extend the runway without dilutive financing. The call reaffirmed the expected recovery trajectory, but the pace and magnitude of the turnaround have yet to show clear acceleration.

Implication

The earnings call reinforces a HOLD stance, as the recovery from reimbursement-driven headwinds is still unfolding with only tentative signs of improvement. While management's outlook suggests stabilization, tangible evidence of sustained procedure growth and concrete payer policy wins is lacking. The constrained cash position heightens execution risk; any shortfall in the expected 2H ramp could accelerate financing pressure. Positive optionality from Cohealyx or PermeaDerm adoption remains on the horizon but is too early to underwrite. Overall, we recommend a cautious approach, maintaining a balanced risk/reward view until clearer proof of a durable upturn materializes.

Thesis delta

The Q2 2026 call updated financials and operational metrics but did not alter our HOLD thesis. Management reiterated the recovery narrative tied to reimbursement advocacy, yet near-term cash consumption and the absence of a clear acceleration in procedure volumes warrant continued caution. A shift to a more bullish stance would require concrete evidence of reimbursement stabilization and sustained procedure growth.